Cuộc họp báo cáo kết quả kinh doanh Quý 3 năm 2026 của OmniAb (OABI): Nâng dự báo doanh thu
Cuộc họp báo cáo kết quả kinh doanh Quý 3/2026 của OmniAb: doanh thu tăng lên 4 triệu USD, dự báo cho cả năm 2026 được nâng lên mức 35-39 triệu USD và tăng trưởng của xPloration tiếp tục là trọng tâm chính.
OmniAb, Inc. licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to identify optimal antibodies and other target-binding proteins for its partners’ drug development efforts. Central to the OmniAb platform, Biological Intelligence, powers the immune systems of its engineered transgenic animals to create optimized antibody candidates for human therapeutics. Its proprietary transgenic animals, including OmniRat, OmniChicken and OmniMouse are genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic and OmniClic are fixed or common light-chain rats and chickens, designed to facilitate the discovery of bispecific antibodies. OmniTaur provides cow-inspired antibodies with unique structural characteristics for challenging targets.